Drugs Controller General of India (DCGI) has given restricted emergency approval to Zydus cadila's anti-viral drug virafin for the moderate covid-19 infections. It will help in faster recovery from covid-19 and will have less complications.
It would be more affordable because it is a single dose regimen. With the use of virafin medicine, there will be less need of supplemental oxygen for the covid-19 patient. It reduces the oxygen distress which is the major challenge for the treatment of covid-19.
In its phase 3 clinical trial, it had shown better improvement in the covid patients. During this trial, several patients were turned RT-PCR negative by 7th day. Prescription of medical expert is required for using this anti-viral drug in the hospital.
In the multicentric trial conducted in 20-25 centers across India, it had shown the lesser need of supplemental oxygen, clearly indicating that it was able to control respiratory distress during the covid-19 treatment. It also shows efficacy against other virus infections, company said.
Multiple doses of Virafin anti-viral drug is also useful in hepatitis B and C. It have been found crucial in the protection against SARS-COV-2.
Dr. Sharvil Patel, Managing director of Cadila healthcare limited, said, "The fact that we are able to offer a therapy which significantly reduces viral load when given early on can help in better disease management. It comes at the much needed time for patients and we will continue to provide them access to critical therapies in this battle against Covid-19."
0 Comments